Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report for 1 January – 30 June 2015

Continued sales growth Second quarter · Net sales increased by 8% to SEK 1,175.4 (1,091.0) million Including divested operations, net sales increased by 6% · Operating profit from the current operating segments amounted to SEK -3.7 (-0.5) million · Including Qliro Financial Services, divested operations and non-recurring items, operating profit amounted to SEK -15.3 (35.0) million · Net income amounted to SEK -10.8 (21.2) million · Basic earnings per share amounted to SEK -0.07 (0.17) · Cash flow from operations, excluding changes in Qliro Financial Services’ lending

Second Quarter Results 2015

CEO Christian Clausen’s comments on the results:“After an exceptional start to the year, we saw in the second quarter a stabilisation of net interest income, a somewhat lower customer activity level in the capital markets, while the strong trend in the savings and investment operations continued, confirming the strong customer demand for our advisory expertise and products. For the first half of the year, total operating income grew 7% in local currencies, while costs in local currencies were down more than 1%, and consequently our cost to income ratio has improved more than 4%-points.

Changes creating conditions for greater stability

Second quarter: April - June 2015 · Total operating revenue amounted to SEK 634 M (767), a decrease of 17%. Revenue decreased organically by 17% (-12%). · Revenue from Desktop and Mobile search amounted to SEK 405 M (489), a decrease of 17%. Revenue from Desktop and Mobile search decreased organically by 17% (-12%).  · Prepaid revenue as per June 30, 2015, amounted to SEK 564 M (633), a decrease of 11% compared with June 30, 2014. · EBITDA amounted to SEK 49 M (168). Earnings were charged with SEK 47 M (-7) in nonrecurring costs, consisting of SEK 12 M (0) in severance pay and

Transcom: Interim report 1 January – 30 June 2015

”Transcom’s revenue and margin increased in Q2. Looking at our rolling 12-month EBIT margin development, we are confirming the steady improvement towards our mid-term target of at least five percent.” Johan Eriksson, President & CEO of Transcom  Key highlights Q2 2015 · Revenue increased by 3.3%, like-for-like 2.6%, driven by higher volumes in the Central & South Europe and Iberia & Latam regions · EBIT margin improved from 0.9% to 3.0%. Excluding items affecting comparability in Q2 2014, the margin improvement was 0.5 percentage points · Profitability improvements in all

Interim Report Q1 1 April-30 June 2015 (3 Months)

1 April - 30 June 2015 (3 months) · Net sales rose by 14 percent to SEK 1,739 million (1,529). · Operating profit rose by 9 percent to SEK 139 million (127) and the operating margin amounted to 8.0 percent (8.3). · Profit after financial items rose by 15 percent to SEK 137 million (119). · Profit after tax amounted to SEK 105 million (91). · Earnings per share totalled SEK 1.55 (1.35). For the most recent 12-month period, earnings per share was SEK 6.10 (5.45). · Cash flow from operations reached SEK 64 million (95). For the most recent 12-month period, cash flow per

Sobi publishes its Report for the Second Quarter 2015 - raises guidance

Swedish Orphan Biovitrum AB (publ)  (Sobi) today announced its results for the second quarter 2015. Revenues for the quarter totalled SEK 764 M (663), an increase of 15 per cent year-on year. The product portfolio grew 25 per cent with Orfadin® and Kineret® delivering strong performance. Business Summary Q2 2015 · European Commission approved Orfadin oral suspension and 20 mg capsule · Sobi's collaboration partner Biogen submitted the Marketing Authorisation Application for Alprolix® (rFIXFc) in Europe · New haemophilia data presented with 23 abstracts at

Sobi exercises opt-in right for Alprolix®

Swedish Orphan Biovitrum  AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Alprolix (rFIXFc) for the territory composed of Europe, North Africa, Russia and certain Middle Eastern markets. Alprolix is a recombinant factor IX Fc fusion protein product candidate for the treatment of haemophilia B. Sobi will make a payment to Biogen of USD 10 million, which will be held in escrow pending the EU regulatory approval of Alprolix.  "This is an important milestone

Seamless has issued SEK 29 million of convertible debentures

Seamless has issued SEK 29 million of convertible debentures. The issue, which was fully subscribed, was sold to private and institutional investors, arranged by Evli Bank PLC, who acted as bookrunners for the deal. The successful completion of this issue gives Seamless an adequate working capital buffer.The board of directors of Seamless resolved to issue these bonds pursuant to the authorization granted at the latest annual general meeting of the company. The convertible loan amounts to a nominal value of not more than SEK 29,000,000 and carries interest at an annual rate of seven (7)

Interim Report Jan-Jun 2015

Reporting period January – June ·Net sales increased by 19.1% to MSEK 3,870 (3,248). Organically, net sales grew by 6.1% ·EBITA increased by 25.2 % to MSEK 583 (465) ·EBITA margin increased to 15.1% (14.3%) ·Earnings before tax grew by 28.3% to MSEK 537 (418) ·Earnings after tax increased by 26.6% to MSEK 397 (314) ·Earnings per share increased by 27.1% to SEK 4.31 (3.39) Reporting period April – June ·Net sales increased by 24.1 % to MSEK 2,122 (1,710). Organically, net sales grew by 12.3% ·EBITA increased by 35.4 % to MSEK 341 (

Elisa's Interim Report January–June 2015

ELISA INTERIM REPORT RELEASE 16 JULY 2015 AT 8:30 AM Second quarter 2015 · Revenue amounted to EUR 390 million (384) · EBITDA was EUR 131 million (127) and EBIT was EUR 79 million (73) · Profit before taxes amounted to EUR 74 million (67) · Earnings per share were EUR 0.38 (0.35) · Cash flow after investments was EUR 70 million (64) · Mobile ARPU grew to EUR 15.7 (15.3 in previous quarter) · Mobile churn decreased to 14.4 per cent (17.7 in previous quarter) · The number of Elisa’s mobile subscriptions increased by 25,200 during the quarter · The number of

Haldex appoints Åke Bengtsson as CFO

Haldex appoints Åke Bengtsson to the role of CFO, joining Haldex by year end, the latest. Åke Bengtsson has extensive financial and leadership experience from the manufacturing industry.Prior to joining Haldex, Åke Bengtsson served as CFO for the Partnertech group, a global industrial partner offering customized solutions throughout the product lifecycle, from product development to manufacturing and aftermarket services. Åke Bengtsson has previously held several leading positions at Cardo, Rexam and Rohm and Haas. He is 52 years old and has a MBA from SIMI in Copenhagen, Denmark. "Åke

Haldex appoints Lena Nordin as SVP Human Resources

Lena Nordin has been promoted to SVP Human Resources and joins the Group Management team. Lena Nordin has worked for Haldex as VP Talent Management since April 2014.Lena Nordin was recruited to a newly formed position as VP Talent Management approximately one year ago. Lena Nordin has during her year at Haldex implemented a number of improvements within areas such as leadership and employee development, employer branding and recruitment. “Lena has gone from strength to strength and we feel that she now is ready to take on the Human Resource responsibility for all of Haldex. Lena has the

Haldex interim report, January - June 2015

Record-high operating marginContinuous efforts to improve our cost base is the main reason for the record-high operating margin. A positive market in North America and Europe is being offset by a negative trend in South America and China, leaving net sales unchanged overall. Weak cash flow due to increase in working capital.  Net sales for Q2 totaled SEK 1,290 (1,124) m, equivalent to an increase of 15% compared with the same period of the previous year. However, net sales were impacted by major exchange rate fluctuations. After currency adjustments, net sales decreased by 1% in Q2.

Intrum Justitia repurchases own shares

On 15th July 2015, the Board of Directors of Intrum Justitia AB (publ) resolved to initiate a share repurchase program. The purpose of the program is to reduce Intrum Justitia’s share capital by cancelling the shares that are repurchased. Through the program, Intrum Justitia will return further funds to shareholders and it is the assessment of the Board of Directors that this will give the company a more optimal capital structure. Intrum Justitia’s Annual General Meeting of April 22, 2015 authorized the Board of Directors to resolve on repurchase of own shares. The Board of Directors has

Interim Report January-June 2015

Highlights during the second quarter · Net asset value amounted to SEK 279,574 m. (SEK 367 per share) on June 30, 2015, a decrease of SEK 16,216 m. (SEK 21 per share) during the quarter, corresponding to a change, including dividend added back, of -3 percent. Over the past 20 years, annual average net asset value growth, with dividend added back, has been 13 percent. · Investor’s new structure was implemented, with investments managed within Listed Core Investments, EQT and Patricia Industries. · Shares were acquired in ABB for a total SEK 2.5 bn. Investor’s ownership reached 9.5

Gjensidige Forsikring ASA: Acquisition of own shares / primary insider trades

On behalf of Gjensidige (OSE:GJF), DNB has on 15 July 2015 acquired 52 331 shares. The shares have been acquired at an average price of NOK 132.8584 per share. 42 922 shares have been sold to employees, at a price of NOK 132.8584 per share, as part of the Gjensidige share savings scheme 2015. The acquisition of shares related to the share savings scheme for the second quarter 2015 is now completed. A total of 7 790 bonus shares are allocated to employees pursuant to the terms of previous years’ share savings scheme. Bonus shares are allocated without further consideration.

Interim Report January - June

Swedbank's President and CEO, Michael Wolf comments: "The dialogue with customers is driving our digital offering. Through stable profit, low risk and high cost efficiency, we create the capacity to invest in our customers.”Interim report for the second quarter 2015Second quarter compared with first quarter 2015 - Resilient result in low interest rate environment- Good cost development- Lending growth in all home markets- Stable net interest income but pressure from lower market interest rates- High customer activity strengthened net commission income- Net gains and losses

INTERIM REPORT JANUARY-JUNE 2015

Consolidated net revenues for the second quarter of 2015 amounted to SEK 1,476 M (1,301). • Operating earnings (EBIT) amounted to SEK 448 M (372). Operating earnings include revaluations of purchased debt portfolios amounting to SEK 45 M (23). The operating margin excluding revaluations was 28 percent (27). • Net earnings for the quarter amounted to SEK 324 M (252) and earnings per share were SEK 4.38 (3.23). • Cash flow from operating activities amounted to SEK 739 M (570). • The carrying amount of purchased debt has increased by 7 percent compared with the year-earlier period.

Tele2 AB: Second Quarter 2015 Result Presentation

The hosts of the presentation are Mats Granryd, President and CEO, Allison Kirkby, CFO and Louise Tjeder, Head of Investor Relations.Tele2 AB will announce its financial results for Q2 2015 at 07:00 am CEST (06:00 am BST/01:00 am EDT) on Tuesday, July 21, 2015. Tele2 will host a presentation with the possibility to join through a conference call, for the global financial community at 10:45 am CEST (09:45 am BST/04:45 am EDT) on Tuesday, July 21, 2015. The presentation will be held in English and also made available as a webcast on Tele2’s website: www.tele2.com. Dial-in information:

Kværner ASA: Second quarter results 2015

16 July 2015 - Growing order intake and activity level in a challenging market. Kvaerner's order intake in the second quarter was NOK 5 674 million, an increase from NOK 5 360 million in the same quarter last year. The company has also continued the high activity level with revenues for the quarter of NOK 3 125 million, an increase of 9 percent from the corresponding quarter last year. Kvaerner has a positive net cash position, a situation that is a particular strength in the current market. The Board has revised the dividend policy to reflect that retaining a solid balance sheet and cash

Kværner ASA: New dividend policy and dividend distribution of NOK 0.15 per share

16 July 2015 - The Board of Directors of Kværner ASA has decided to revise the company's dividend policy to reflect the developments in Kvaerner's long term markets and outlook. The last review of the dividend policy was in 2012.The Board's current priorities when proposing the level of dividends are to retain a strong balance sheet and cash position. The new policy will be implemented with immediate effect. Kværner ASA's dividend policy is based on semi-annual dividend payments. Decisions as to dividend payments depend on outlook, liquidity and considerations such as alternative use of

ROI awards grants to Drs. David Sher and Anand Shah for projects to examine the comparative value of radiation therapy

The Radiation Oncology Institute (ROI) has selected David J. Sher, MD, MPH, an associate professor in the Department of Radiation Oncology at the University of Texas—Southwestern Medical Center in Dallas, and Anand Shah, MD, MPH, a post-doctoral residency fellow in the Department of Radiation Oncology at Columbia University Medical Center in New York to receive grants for their projects to examine the comparative value of radiation therapy (RT), in response to ROI’s Request for Proposals (RFP) issued earlier this year. Sher’s project is titled “Comparative value of transoral surgery and

Anuvia Plant Nutrients Appoints Amy J. Yoder as CEO to Lead New Company

Anuvia™ Plant Nutrients, a new plant nutrient company to be headquartered in Zellwood, Florida, has hired Amy Yoder as its CEO. Anuvia is focused on a new, innovative and patented way of manufacturing an enhanced efficiency fertilizer (EEF) for the turf and agricultural industries. In today’s ever-growing world, sustainability is key. Anuvia addresses the three pillars of sustainability – social, environmental and economic – simultaneously by providing an avenue for organic materials to be used in a resource-efficient and environmentally friendly manner. “We’re very excited to have

CHC receives $1.2 Million in Federal Grant Commitment for Nurse Care Coordination Program

Community Health Center, Inc. (CHC), Connecticut’s largest primary care provider for the underserved population, headquartered in Middletown, CT, announced today that it has received a federal grant   from the Health Resources and Services Administration (HRSA) to improve patient’s health outcomes by expanding nurse care coordination to its state-wide network of health centers over the next three years. The project has three primary goals: to improve and expand the Interprofessional Collaborative Practice  environment agency-wide by developing CHC’s  care coordination program,   to build

There are no items matching the current filter
There are no more items matching the current filter
Back to top